Matteo Bassetti to Pseudomonas Infections
This is a "connection" page, showing publications Matteo Bassetti has written about Pseudomonas Infections.
Connection Strength
3.048
-
The ideal patient profile for new beta-lactam/beta-lactamase inhibitors. Curr Opin Infect Dis. 2018 12; 31(6):587-593.
Score: 0.531
-
Rational approach in the management of Pseudomonas aeruginosa infections. Curr Opin Infect Dis. 2018 12; 31(6):578-586.
Score: 0.531
-
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019 Apr; 53(4):408-415.
Score: 0.529
-
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant. Infection. 2018 Apr; 46(2):263-265.
Score: 0.492
-
Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam. J Glob Antimicrob Resist. 2017 06; 9:100-102.
Score: 0.476
-
Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest. 2020 Oct; 50(10):e13319.
Score: 0.149
-
Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother. 2018 03 01; 73(3):664-671.
Score: 0.126
-
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob Chemother. 2017 05 01; 72(5):1386-1395.
Score: 0.119
-
[Diagnostic and therapeutic management of Gram-negative infections]. Infez Med. 2008 Apr; 16 Suppl2:22-9.
Score: 0.063
-
Ceftolozane/tazobactam: place in therapy. Expert Rev Anti Infect Ther. 2018 04; 16(4):307-320.
Score: 0.032